June 14, 2016
Targovax granted US Patent for oncolytic virus ONCOS-102
Media
June 10, 2016
Pre-dosing NHL patients with HH1 anti-CD37 antibody before Betalutin® increases its pharmacokinetic exposure and reduces its haematological toxicity
June 09, 2016
Strongbridge Biopharma plc Announces Executive Promotion and Leadership Transition Fredric Cohen, M.D., Promoted to Senior Vice President, Global Research & Development
June 09, 2016
Targovax receives regulatory approval in Spain to conduct a clinical trial with its oncolytic virus ONCOS-102
June 08, 2016
GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
June 07, 2016
Targovax ASA: Patient recruitment for TG01 immuno-oncology trial completed
June 06, 2016
Aprea AB announces efficacy and safety data in high-grade serous ovarian cancer patients treated with investigational APR-246 presented at 2016 ASCO Annual Meeting
June 02, 2016
Strongbridge Biopharma plc Announces Presentation at Jefferies 2016 Healthcare Conference
June 02, 2016
Publication of the LOCATION clinical study results in the renowned scientific journal of the European Atherosclerosis Society (EAS)
June 02, 2016
Targovax receives approval in Australia to conduct a clinical trial withTG02 – an immunotheraphy treatment targeting RAS mutations
